By 2018, half of Medicare spending outside of managed care will be tied to incentives to manage quality and costs, federal officials said Monday. That was greeted with enthusiasm but also with warnings that the effort will be wasted if the new models are too weak or built on flawed measures.
Medicare's new five-star quality-rating system for dialysis facilities suggests significant disparities between the care provided by the nation's largest kidney-care companies. Far fewer Fresenius Medical Care facilities earned five- and four-star ratings than those of competitor DaVita Kidney Care.
A list of the nation's 20 largest healthcare finance companies, ranked by amount of loans underwritten in the healthcare sector underwritten in 2014. Source: Dealogic. Published Jan. 24, 2015, p. 34.
The Obama administration wants 30% of payments for traditional Medicare benefits to be tied to alternative payment models such as accountable care organizations by the end of 2016. The administration also has set a goal of hitting 50% by the end of 2018.
The health insurance sector saw two takeover deals Monday, both of which aim to add expertise in care coordination and population-health management.
The CMS is taking a deep data dive into Medicaid enrollment data to uncover just how many new adults have joined the state programs since the Affordable Care Act motivated many states to expand eligibility last year.
Healthways, a Franklin, Tenn.-based developer of wellness and population-health management programs, has hired an investment bank to advise it on a long-term strategy. The move could lead to a sale of the company, among other alternatives.
Jerrit Tan, a first-generation Chinese-American, used to skip school to act as a translator for his immigrant parents and extended family when they visited a doctor. Now he has developed a smartphone app that provides medical interpretation services in 15 languages.
Researchers and cost-control advocates are increasingly questioning drugs, devices and procedures that proved effective in clinical trials but don't achieve the same outcomes once widely deployed. Sometimes they perform worse than cheaper alternatives already on the market.